New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas - 12/08/11
, Christoph Niermann, MD a, Rudolf-Josef Fischer, MD, PhD b, Hans-Joachim Schulze, MD, PhD a
Reprint requests: Christian Hallermann, MD, Dorbaumstrasse 300, 48157 Munster, Germany.Munster, Germany
Abstract |
Background |
There is a growing body of literature that has enhanced our understanding of the biology of primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) including in the context of gene profiling studies. Recent studies have demonstrated an activated proliferation profile associated with leg type lymphoma including overexpression of proto-oncogenes PIM1, PIM2, and cMYC, and the transcription factors MUM1 and OCT2. Although gene profiling is very useful in understanding the molecular basis of diffuse large B-cell lymphoma (LBCL), it is not practical from a routine diagnostic perspective. In this regard, the purpose of the study was to further define an armamentarium of easily applied immunohistochemical stains to accurately prognosticate PCDLBCL.
Methods |
In all, 35 patients with PCDLBCL, 14 of follicle center and 21 of leg type, were analyzed using antibodies against CD5, CD138, BCL2, BCL6, OCT2, MUM1, FOXP1, and cMYC. Findings were correlated with clinical data.
Results |
All cases stained negative for CD5 and CD138. Both subtypes differed in distinct staining patterns for BCL6, BCL2, OCT2, MUM1, and FOXP1. Staining for BCL2, OCT2, and/or MUM1 was associated with poor, and BCL6 with a favorable prognosis. Expression of cMYC was irrespective of prognosis or subtype, whereas ulceration or primary manifestation on the leg or multiple lesions was indicative for worse prognosis.
Limitations |
Case number was a limitation.
Conclusion |
Discriminating PCDLBCL supports the validity of the World Health Organization/European Organization for Research and Treatment of Cancer classification. To identify risk factors in patients with PCDLBCL we recommend thorough evaluation of clinical presentation and exploratory staining pattern for BCL2, BCL6, MUM1 and OCT2.
Le texte complet de cet article est disponible en PDF.Abbreviations used : ABC, DSS, EORTC, GC, LBCL, LBCL-L, LFCL, OS, PCDLBCL, WHO
Plan
| Funding sources: None. Conflicts of interest: None identified. |
Vol 56 - N° 4
P. 588-597 - avril 2007 Retour au numéro
Article précédent
- Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma
- Jacob A. Sepmeyer, John P. Greer, Tatsuki Koyama, John A. Zic
- A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis
- Angela Moore, Kenneth B. Gordon, Sewon Kang, Alice Gottlieb, Bruce Freundlich, H. Amy Xia, Seth R. Stevens
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?